Katherine Narr discusses effects of ketamine versus ECT when treating refractory depression

June 29, 2019

In a recent press release by MDedge Psychiatry – an online journalism resource – Katherine Narr, associate professor of neurology and psychiatry and biobehavioral sciences at the David Geffen School of Medicine, discussed the results from a study performed as part of the Depression Grand Challenge’s Serial Ketamine Infusion Biomarkers demonstration project.

The study evaluated the effects that fast-acting treatment interventions like electroconvulsive therapy (ECT) and serial ketamine infusion have on treatment-resistant depression. Narr shared that “Over the short term,’ even a single ketamine infusion may ’be as effective as … ECT for reducing overall depression, apathy, anhedonia, and suicidal ideation,’ but ECT may be more durable…”

Read more at MDedge Psychiatry.

This study was made possible thanks to funding from the National Institute of Mental Health (NIMH). See the Human Studies Demonstration Project Guide to learn more about the biomarkers of fast acting treatment study.